WO2020217143A1 - Composition de poudre sèche inhalable comprenant du glycopyrronium, de l'indacatérol et de la fluticasone - Google Patents

Composition de poudre sèche inhalable comprenant du glycopyrronium, de l'indacatérol et de la fluticasone Download PDF

Info

Publication number
WO2020217143A1
WO2020217143A1 PCT/IB2020/053617 IB2020053617W WO2020217143A1 WO 2020217143 A1 WO2020217143 A1 WO 2020217143A1 IB 2020053617 W IB2020053617 W IB 2020053617W WO 2020217143 A1 WO2020217143 A1 WO 2020217143A1
Authority
WO
WIPO (PCT)
Prior art keywords
dry powder
lactose
pharmaceutically acceptable
powder composition
particle size
Prior art date
Application number
PCT/IB2020/053617
Other languages
English (en)
Inventor
Sushrut Kulkarni
Sunil Chaudhari
Girish TRIVEDI
Ganesh JADHAV
Raveendra Pai
Original Assignee
Glenmark Pharmaceutical Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceutical Limited filed Critical Glenmark Pharmaceutical Limited
Publication of WO2020217143A1 publication Critical patent/WO2020217143A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Definitions

  • the present invention relates to an inhalable pharmaceutical dry powder composition comprising two or more active ingredients that are useful for pulmonary administration.
  • the present invention relates to an inhalable pharmaceutical dry powder composition comprising effective amounts of glycopyrronium or its pharmaceutically acceptable salt, indacaterol or its pharmaceutically acceptable salt, fluticasone or its pharmaceutically acceptable ester and a diluent; and process of preparing such composition and its use in the treatment of respiratory disorders.
  • Respiratory disorders related to airway inflammation include a number of lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
  • COPD chronic obstructive pulmonary disease
  • Asthma is a disease characterized by an increased responsiveness of the trachea and bronchi to various stimuli, and manifested by widespread narrowing of the airways that changes in severity either spontaneously or as a result of treatment.
  • the events leading to airway obstruction in asthma include edema of airway walls, infiltration of inflammatory cells into the lung, production of various inflammatory mediators and increased mucous production.
  • the current therapy for asthma includes bronchodilator drugs, corticosteroids and leukotriene antagonists.
  • Bronchodilator drugs dilate the bronchi and bronchioles, decreasing resistance in the respiratory airway and increasing airflow to the lungs.
  • Corticosteroid drugs are effective at reducing asthma symptoms by blocking the body's inflammatory response.
  • the leukotriene antagonists have limited efficacy, with only small increases in pulmonary function demonstrated in clinical trials.
  • COPD is a term used to classify two major airflow obstruction disorders: chronic bronchitis and emphysema.
  • Chronic bronchitis is inflammation of the bronchial airways.
  • Emphysema is inflammation of the alveoli, or air sacs in the lungs.
  • Emphysema has a number of causes, including smoking, exposure to environmental pollutants, alpha-one antitrypsin deficiency, and aging.
  • COPD is a disease of the respiratory apparatus, characterized by an irreversible obstruction of the airways, of a degree that varies according to the gravity.
  • Indacaterol is a long acting, beta-2 adrenergic agonist. Its chemical name is 5- ⁇ (lR)-2-((5,6-Diethyl-2, 3-dihydro- lH-inden-2-yl)amino)-l-hydroxyethyl ⁇ -8-hydroxy quinolin-2(lH)-one. It is structurally depicted as:
  • Indacaterol is currently available in U.S. as Arcapta Neohaler (Approved as indacaterol maleate equivalent to 75mcg of indacaterol as powder for inhalation). Indacaterol maleate is available in combination with glycopyrrolate under the brand name Utibron as powder for inhalation composition. Both the products are used as maintenance treatment of COPD.
  • Glycopyrronium is a long acting muscarinic antagonist. Its chemical name is 3- (2-cyclopentyl-2-hydroxy-2-phenylacetoxy)- 1 , 1 -dimethylpyrrolidinium. It has following structure:
  • Glycopyrronium bromide (also known as Glycopyrrolate) is currently approved in the U.S. as Robinul ® (as 0.2mg/ml injection and as tablets of lmg strength); which is indicated for treatment of peptic ulcer and as preoperative anti-muscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions in anesthesia.
  • Glycopyrronium bromide is also approved in Europe as dry powder inhaler Seebri Breezhaler ® (Novartis) which is indicated for the treatment of COPD. Seebri Breezhaler is presented as an inhalation powder in hard capsules. Each capsule contains 63 meg of glycopyrronium bromide, equivalent to 50 meg of glycopyrronium.
  • SeebriTM Neohaler ® glycopyrrolate inhalation powder 15.6 meg as a stand-alone monotherapy for the same COPD indication.
  • SeebriTM Neohaler and Seebri Breezhaler ® contains lactose and magnesium stearate as inactive ingredients.
  • Fluticasone propionate is a corticosteroid used to treat asthma and allergic rhinitis.
  • the chemical name for fluticasone propionate is S-(fluoromethyl)-6a, 9- difluoro- 11 b, 17-dihydroxy- 16a-methyl-3-oxoandrosta- 1 ,4-diene- 17P-carbothioate 17- propanoate. It has the following structure.
  • GlaxoSmithKline currently markets fluticasone propionate as FLOVENT ® (USA and Canada) and FLIXOTIDE (EU) for asthma, and as FLONASE ® (USA and Canada), FLIXONASE ® and PIRINASE ® for allergic rhinitis (hay fever), as well as a combination of fluticasone and salmeterol as ADVAIR ® (USA and Canada) or SERETIDE ® .
  • International Publication No. WO 2005/105043 relates to dry powder compositions which exhibit improved stability over time comprising glycopyrronium, and methods for producing the same.
  • International Publication No. WO 2005/110402A1 relates to medicament comprising glycopyrrolate and indacaterol for the treatment of an inflammatory or obstructive airway disease.
  • WO 2012/110770 relates to medicament comprising glycopyrrolate, indacaterol maleate and fluticasone furoate for the treatment of respiratory, inflammatory or obstructive airway disease.
  • the present invention relates to an inhalable pharmaceutical dry powder composition
  • an inhalable pharmaceutical dry powder composition comprising an effective amount of glycopyrronium or its pharmaceutically acceptable salt, an effective amount of indacaterol or its pharmaceutically acceptable salt, fluticasone or its pharmaceutically acceptable ester and a diluent.
  • an inhalable pharmaceutical dry powder composition comprising an effective amount of glycopyrronium or its pharmaceutically acceptable salt; an effective amount of indacaterol or its pharmaceutically acceptable salt such as hydrochloride, maleate, acetate etc; fluticasone or its pharmaceutically acceptable ester such furoate, propionate etc and a diluent, wherein said composition is free from a hydrophobic excipient.
  • an inhalable pharmaceutical dry powder composition comprising an effective amount of glycopyrrolate, an effective amount of indacaterol hydrochloride, an effective amount of fluticasone propionate and a diluent, wherein said composition is free from a hydrophobic excipient.
  • the pharmaceutically acceptable diluent suitable for use in the present invention is selected from lactose, mannitol, sucrose, trehalose, cyclodextrin, or mixtures thereof.
  • the pharmaceutically acceptable diluent is lactose monohydrate.
  • the present invention relates to an inhalable pharmaceutical dry powder composition
  • an inhalable pharmaceutical dry powder composition comprising (i) a co-micronized premix consisting of glycopyrronium or its pharmaceutically acceptable salt and lactose; (ii) indacaterol hydrochloride and fluticasone or its pharmaceutically acceptable ester and (iii) lactose; wherein said composition is free from a hydrophobic excipient.
  • the present invention relates to an inhalable pharmaceutical dry powder composition
  • an inhalable pharmaceutical dry powder composition comprising (a) glycopyrronium bromide in an amount of 5 meg to 100 meg, (b) indacaterol hydrochloride in an amount of 5 meg to 500 meg (c) fluticasone propionate in an amount of 25 meg to 1000 meg and (d) lactose wherein said composition is free from a hydrophobic excipient.
  • the present invention relates to an inhalable pharmaceutical dry powder composition
  • an inhalable pharmaceutical dry powder composition comprising glycopyrronium or its pharmaceutically acceptable salt from about 0.01% w/w to about 5% w/w or from about 0.05% w/w to about 2.5% w/w or from about 0.1% w/w to about 1% w/w, indacaterol hydrochloride from about 0.01% w/w to about 5% w/w or from about 0.05% w/w to about 3% w/w or from about 0.075% w/w to about 2.5% w/w and fluticasone or its pharmaceutically acceptable ester from about 0.01% w/w to about 5% w/w or from about 0.05% w/w to about 3% w/w or from about 0.075% w/w to about 2.5% w/w by total weight of inhalable composition.
  • an inhalable pharmaceutical dry powder composition wherein the composition has fine particle mass in the range of about 0.03 mg to about 10 mg having average particle size less than 80 pm or less than 60 pm or less than 50 pm
  • coarse particle mass in the range of about 5 mg to about 50 mg having average particle size more than 80 pm but less than 350 pm, preferably more than 90 pm or more than 100 pm, of the total inhalable composition
  • an inhalable pharmaceutical dry powder composition wherein the composition has fine lactose particles in the range of about 0.5 mg to about 15 mg having average particle size less than 80 pm or less than 60 pm or less than 50 pm and coarse lactose particles in the range of about 10 mg to about 30mg having average particle size more than 80 pm but less than 350 pm, preferably more than 90 pm or more than 100 pm, of total weight of inhalable composition.
  • an inhalable pharmaceutical dry powder composition wherein the composition has fine lactose particle mass in the range of about 0.1% w/w to about 40% w/w having average particle size less than 80 pm and coarse lactose particles in the range of about 50% w/w to about 99.9% w/w by having average particle size more than 80 pm but less than 350 pm, preferably more than 90 pm or more than 100 pm of total weight of inhalable composition.
  • an inhalable pharmaceutical dry powder composition comprising a co-micronized premix consisting of glycopyrronium or its pharmaceutically acceptable salt and one part of lactose in the weight ratio of about 1:1 to about 1:100 wherein D90 particle size of lactose is in the range of 140 pm to about 210 pm prior to co-micronization process.
  • the diluent is a admixture of lactose particles consisting of: (i) about to 0 to 10% w/w of fine particles of lactose having particle size D90 less than about 50 pm; and (ii) about 90 to 99.9 % w/w of coarse lactose having particle size D90 in the range of about 30 pm to about 350 pm.
  • an inhalable pharmaceutical dry powder composition comprising (i) a co-micronized premix consisting of glycopyrronium or its pharmaceutically acceptable salt and one part of lactose in the weight ratio of about 1:1 to about 1:100 wherein D90 particle size of co-micronized premix is in the range of about 0.5 pm to about 10 pm; (ii) indacaterol or its pharmaceutically acceptable salt and fluticasone or its pharmaceutically acceptable ester; and (iii) another part of lactose having D90 particle size in the range of about 5 pm to about 400 pm; wherein said composition is free from a hydrophobic excipient.
  • an inhalable pharmaceutical dry powder composition comprising (i) a co-micronized premix consisting of glycopyrronium or its pharmaceutically acceptable salt and one part of lactose in the weight ratio of about 1:1 to about 1:100 wherein D90 particle size of co-micronized premix is in the range of about 1 pm to about 8 pm; (ii) indacaterol or its pharmaceutically acceptable salt and fluticasone or its pharmaceutically acceptable ester; and (iii) another part of lactose having D90 particle size in the range of about 30 pm to about 350 pm; wherein said composition is free from a hydrophobic excipient.
  • the weight ratio of fine particle mass to coarse particle mass in the present inhalable composition ranges from about 1:1 to about 1:100.
  • step (b) Blending the co-micronized premix of step (a) with an effective amount of indacaterol hydrochloride, fluticasone or its pharmaceutically acceptable ester and one part of lactose
  • step (c) Blending the mixture obtained in step (b) with another part of lactose, wherein said composition is free from a hydrophobic excipient and wherein said composition has fine particle mass in the range of 0.2 mg to 20 mg and coarse particle mass in the range of about 5 mg to about 50 mg, of the total inhalable composition.
  • step (b) Blending the co-micronized premix of step (a) with an effective amount of indacaterol hydrochloride, fluticasone or its pharmaceutically acceptable ester and fine particle of lactose having average particle size less than 80 pm or less than 60 pm or less than 50 pm
  • step (c) Blending the mixture obtained in step (b) with coarse particles of lactose having average particle size more than 80 pm or more than 90 pm or more than 100 pm.
  • composition is free from a hydrophobic excipient and wherein said composition has fine particle mass in the range of 0.2 mg to 20 mg and coarse particle mass in the range of about 5 mg to about 50 mg, of the total inhalable composition.
  • the present invention relates to a method of treating respiratory disorders in a subject, said method comprising administering by inhalation route to the subject the dry powder composition comprising an effective amount of glycopyrronium bromide, indacaterol hydrochloride and fluticasone propionate, wherein said composition is free from hydrophobic agent.
  • the present invention relates to use of an effective amount of glycopyrronium bromide and indacaterol hydrochloride in the inhalable pharmaceutical dry powder composition of the present invention for the treatment of respiratory disorders in a subject.
  • an excipient includes a single excipient as well as two or more different excipients, and the like.
  • Glycopyrrolate is a quaternary ammonium salt.
  • Suitable counter ions are pharmaceutically acceptable counter ions including, for example, fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p- chlorobenzoate, diphenyl- acetate or triphenylacetate, o-hydroxybenzoate, p- hydroxybenzoate, 1- hydroxynaphthalene-2-carboxylate, 3-hydroxynaphthalene-2- carboxylate, methane- sulfonate and benzenesulfonate.
  • glycopyrronium bromide is glycopyrronium bromide.
  • Glycopyrrolate has two centers of asymmetry (chiral centers), and can exist in four stereoisometric forms namely (3R, 2'R)-, (3S, 2'R)-, (3R, 2'S)- and (3S, 2'S).
  • salts or esters are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, and allergic response, commensurate with a reasonable benefit to risk ratio, and effective for their intended use.
  • Representative acid additions salts include the hydrochloride, furoate, hydrobromide, sulphate, bisulphate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, mesylate, citrate, maleate, fumarate, succinate, tartrate, ascorbate, glucoheptonate, lactobionate, and lauryl sulphate salts.
  • Representative alkali or alkaline earth metal salts include the sodium, calcium, potassium and magnesium salts.
  • an effective amount and “therapeutically effective amount” are interchangeable and denotes an amount of an active ingredient that, when administered to a subject for treating respiratory disorders, produces an intended therapeutic benefit in a subject.
  • active ingredient used interchangeably with“active” or“active substance” or“drug”) as used herein includes Glycopyrronium or a pharmaceutically acceptable salt thereof.
  • treating also covers the prophylaxis, mitigation, prevention, amelioration, or suppression of a disorder modulated by the Glycopyrronium or its salt in a mammal.
  • subject includes mammals like human and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).
  • domestic animals e.g., household pets including cats and dogs
  • non-domestic animals such as wildlife
  • the subject is a human.
  • pharmaceutically acceptable excipients any of the components of a pharmaceutical composition other than the actives and which are approved by regulatory authorities or are generally regarded as safe for human or animal use.
  • the term "average particle size” refers to the distribution of particles, wherein about 50 volume percent of all the particles measured have a size less than the defined average particle size value and about 50 volume percent of all measurable particles measured have a particle size greater than the defined average particle size value. This can be identified by the term “D50” or“d (0.5)”.
  • D90 value relates to about 90 volume percent of all the particles measured have a size less than the defined particle size value (also referred to as“D90 particle size’) and Dio value refers to about 10 volume percent of all the particles measured have size less than a defined particle size value (also referred to as Dio particle size).
  • the particle size can be measured using various techniques like laser diffraction, photon correlation spectroscopy (PCS) and Coulter’s principle.
  • term“fine particles” refer to the particles with D10 value of about 0.1 pm to about 20 pm, D50 value of about 1 pm to about 45 pm and D90 value less than 65 pm
  • term“coarse particles” refer to the particles with D10 value of about 60 mih to about 200 mih, Dso value of about 80 mih to about 300 mih and D90 value less than 320 mhi.
  • the therapeutically effective amount of fluticasone or its pharmaceutically acceptable ester to be administered per day ranges from about 1 pg to about 1000 pg, and preferably from about 10pg to about 800 pg and more preferably from about 20 pg to about 500 pg.
  • the therapeutically effective amount of indacaterol or its pharmaceutically acceptable salt to be administered per day ranges from about 1 meg to about 1000 meg, and preferably from about 10 meg to about 800 meg, and more preferably from about 20 meg to about 600.
  • the therapeutically effective amount of fluticasone or its pharmaceutically acceptable ester to be administered per day ranges from about 1 pg to about 1000 pg, and preferably from about 10pg to about 800 pg and more preferably from about 20 pg to about 500 pg.
  • the therapeutically effective amount of glycopyrronium or its pharmaceutically acceptable salt to be administered per day ranges from about 1 meg to about 500 meg, and preferably from about 5 meg to about 250 meg, and more preferably from about 10 meg to about 100 meg.
  • co-micronisation refers to milling or micronisation of the active ingredient and lactose together in suitable mill to obtain micronised mixture of active ingredient and lactose.
  • the mixture of active ingredient and lactose after co-micronisation process can be called as co-micronised premix of active ingredient and lactose.
  • Jet mill, Air jet mill, Ball mill and the like can be used for the milling purpose.
  • Air Jet Mill may be used for co-micronisation.
  • the fine particle mass test is normally conducted using a validated multistage impactor or impinger method, or a suitably validated alternative. It is normally considered acceptable to set upper and lower limits on the results of pooled stages corresponding to a particle size distribution of less than 5 micrometer, although alternative limits may be found acceptable with adequate justification.
  • the drug mass should be reported rather than the percentage of emitted dose (or other derived parameter).
  • the Mass Median Aerodynamic Diameter (MMAD) is defined as the diameter at which 50% of the particles by mass are larger and 50% are smaller determined by suitable multistage impactor or impinger method
  • composition in the above embodiments may optionally comprise one or more pharmaceutically acceptable excipients.
  • the inhalable pharmaceutical dry powder composition of the present invention may contain one or more pharmaceutically acceptable excipients.
  • the powder composition may be further be filled into a capsule for inhalation or may be processed into a lightly compressed tablet or powder agglomeration which can be easily crushed to obtain a powder for inhalation.
  • the composition can be filled, either as discrete dosage units, in a blister or a sachet or in a reservoir for multiple use.
  • the present invention relates to an inhalable pharmaceutical dry powder composition
  • an inhalable pharmaceutical dry powder composition comprising an effective amount of glycopyrronium or its pharmaceutically acceptable salt, an effective amount of indacaterol or its pharmaceutically acceptable salt, fluticasone or its pharmaceutically acceptable ester and a diluent.
  • an inhalable pharmaceutical dry powder composition comprising an effective amount of glycopyrronium or its pharmaceutically acceptable salt, an effective amount of indacaterol or its pharmaceutically acceptable salt, fluticasone or its pharmaceutically acceptable ester and a diluent, wherein said composition is free from a hydrophobic excipient.
  • an inhalable pharmaceutical dry powder composition comprising an effective amount of glycopyrrolate, an effective amount of indacaterol hydrochloride, an effective amount of fluticasone propionate and a diluent, wherein said composition is free from a hydrophobic excipient.
  • the pharmaceutically acceptable diluent suitable for use in the present invention is selected from lactose, mannitol, sucrose, trehalose, cyclodextrin, or mixtures thereof.
  • the pharmaceutically acceptable diluent is lactose, preferably lactose monohydrate.
  • lactose Various grade of lactose are available for use in dry powder compositions and are selected from Respitose ® SV010, Respitose ® SV003, Respitose ® ML006, Lactose Monohydrate Inhalation 40M, Lactose Anhydrous 120M, Lactohale ® 200, Lactohale ® 300, Lactohale ® 70, Inhalac 500 and the like.
  • the present invention relates to an inhalable pharmaceutical dry powder composition
  • an inhalable pharmaceutical dry powder composition comprising (i) a co-micronized premix consisting of glycopyrronium or its pharmaceutically acceptable salt and lactose; (ii) indacaterol hydrochloride and fluticasone or its pharmaceutically acceptable ester and (iii) lactose; wherein said composition is free from a hydrophobic excipient.
  • the present invention relates to an inhalable pharmaceutical dry powder composition
  • dry mix comprising (i) glycopyrronium or its pharmaceutically acceptable salt (ii) indacaterol hydrochloride (iii) fluticasone or its pharmaceutically acceptable ester and (iv) lactose; wherein said composition is free from a hydrophobic excipient.
  • the present invention relates to an inhalable pharmaceutical dry powder composition
  • an inhalable pharmaceutical dry powder composition comprising (a) glycopyrronium bromide in an amount of 5 meg to 100 meg, (b) indacaterol hydrochloride in an amount of 5 meg to 500 meg (c) fluticasone propionate in an amount of 25 meg to 1000 meg and (d) lactose wherein said composition is free from a hydrophobic excipient.
  • the present invention relates to an inhalable pharmaceutical dry powder composition
  • an inhalable pharmaceutical dry powder composition comprising glycopyrronium or its pharmaceutically acceptable salt from about 0.01% w/w to about 5% w/w or from about 0.05% w/w to about 2.5% w/w or from about 0.1% w/w to about 1% w/w, indacaterol hydrochloride from about 0.01% w/w to about 5% w/w or from about 0.05% w/w to about 3% w/w or from about 0.075% w/w to about 2.5% w/w and fluticasone or its pharmaceutically acceptable ester from about 0.01% w/w to about 5% w/w or from about 0.05% w/w to about 3% w/w or from about 0.075% w/w to about 2.5% w/w by total weight of inhalable composition.
  • an inhalable pharmaceutical dry powder composition wherein the composition has fine particle mass in the range of about 0.03 mg to about 10 mg having average particle size less than 80 pm or less than 60 pm or less than 50 pm
  • coarse particle mass in the range of about 5 mg to about 50 mg having average particle size more than 80 pm but less than 350 pm, preferably more than 90 pm or more than 100 pm, of the total inhalable composition
  • an inhalable pharmaceutical dry powder composition wherein the composition has fine lactose particles in the range of about 0.5 mg to about 15 mg having average particle size less than 80 pm or less than 60 pm or less than 50 pm and coarse lactose particles in the range of about 10 mg to about 30mg having average particle size more than 80 pm but less than 350 pm, preferably more than 90 pm or more than 100 pm, of total weight of inhalable composition.
  • an inhalable pharmaceutical dry powder composition wherein the composition has fine lactose particle mass in the range of about 0.1% w/w to about 40% w/w having average particle size less than 80 pm and coarse lactose particles in the range of about 50% w/w to about 99.9% w/w by having average particle size more than 80 pm but less than 350 pm, preferably more than 90 pm or more than 100 pm of total weight of inhalable composition.
  • an inhalable pharmaceutical dry powder composition comprising a co-micronized premix consisting of glycopyrronium or its pharmaceutically acceptable salt and one part of lactose in the weight ratio of about 1:1 to about 1:100 wherein D90 particle size of lactose is in the range of 140 pm to about 210 pm prior to co-micronization process.
  • the diluent is a admixture of lactose particles consisting of: (i) about to 0 to 10% w/w of fine particles of lactose having particle size D90 less than about 50 pm; and (ii) about 90 to 99.9 % w/w of coarse lactose having particle size D90 in the range of about 30 pm to about 350 pm.
  • an inhalable pharmaceutical dry powder composition comprising (i) a co-micronized premix consisting of glycopyrronium or its pharmaceutically acceptable salt and one part of lactose in the weight ratio of about 1:1 to about 1:100 wherein D90 particle size of co-micronized premix is in the range of about 0.5 pm to about 10 pm; (ii) indacaterol or its pharmaceutically acceptable salt and fluticasone or its pharmaceutically acceptable ester; and (iii) another part of lactose having D90 particle size in the range of about 5 pm to about 400 pm; wherein said composition is free from a hydrophobic excipient.
  • an inhalable pharmaceutical dry powder composition comprising (i) a co-micronized premix consisting of glycopyrronium or its pharmaceutically acceptable salt and one part of lactose in the weight ratio of about 1:1 to about 1:100 wherein D90 particle size of co-micronized premix is in the range of about 1 pm to about 8 pm; (ii) indacaterol or its pharmaceutically acceptable salt and fluticasone or its pharmaceutically acceptable ester; and (iii) another part of lactose having D90 particle size in the range of about 30 pm to about 350 pm; wherein said composition is free from a hydrophobic excipient.
  • the weight ratio of fine particle mass to coarse particle mass in the present inhalable composition ranges from about 1:1 to about 1:100.
  • step (b) Blending the co-micronized premix of step (a) with an effective amount of indacaterol hydrochloride, fluticasone or its pharmaceutically acceptable ester and one part of lactose
  • step (c) Blending the mixture obtained in step (b) with another part of lactose, wherein said composition is free from a hydrophobic excipient and wherein said composition has fine particle mass in the range of 0.2 mg to 20 mg and coarse particle mass in the range of about 5 mg to about 50 mg, of the total inhalable composition.
  • step (b) Blending the co-micronized premix of step (a) with an effective amount of indacaterol hydrochloride, fluticasone or its pharmaceutically acceptable ester and fine particle of lactose having average particle size less than 80 pm or less than 60 pm or less than 50 pm
  • step (c) Blending the mixture obtained in step (b) with coarse particles of lactose having average particle size more than 80 pm or more than 90 pm or more than 100 pm. wherein said composition is free from a hydrophobic excipient and wherein said composition has fine particle mass in the range of 0.2 mg to 20 mg and coarse particle mass in the range of about 5 mg to about 50 mg, of the total inhalable composition.
  • the weight ratio of glycopyrronium or its pharmaceutically acceptable salt to lactose in the co-micronized premix of the present invention ranges from about 1:1 to about 1:300, from about 1:5 to about 1:200 or from about 1:10 to about 1:100.
  • the weight ratio of the co-micronized premix to lactose ranges from about 1: 1 to about 1:50, preferably from about 1:5 to about 1:30.
  • the weight ratio of fine lactose to coarse lactose ranges from about 1:1 to about 1:80.
  • an inhalable pharmaceutical dry powder composition comprising (a) glycopyrronium bromide (b) indacaterol hydrochloride (c) fluticasone propionate and (d) lactose, wherein said composition is free from hydrophobic agents selected from amino acids, fatty acids, peptides, talc, stearic acid and its derivatives such as calcium stearate, magnesium stearate.
  • an inhalable pharmaceutical dry powder composition comprising an effective amount of glycopyrronium or its salt, indacaterol hydrochloride and lactose wherein Median mass aerodynamic diameter (MMAD) of said composition is in the range of 1 pm - 6 pm or more preferably in the range of 2.5 pm - 4.5 pm.
  • MMAD Median mass aerodynamic diameter
  • the present invention relates to a method of treating respiratory disorders in a subject, said method comprising administering by inhalation route to the subject the dry powder composition comprising an effective amount of glycopyrronium bromide, indacaterol hydrochloride and fluticasone propionate, wherein said composition is free from hydrophobic agent.
  • the present invention relates to use of an effective amount of glycopyrronium bromide and indacaterol hydrochloride in the inhalable pharmaceutical dry powder composition of the present invention for the treatment of respiratory disorders in a subject.
  • the respiratory disorder in the context of present invention, includes but is not limited to asthma, emphysema, bronchitis, COPD, sinusitis, respiratory depression, reactive airways dysfunction syndrome (RADS), acute respiratory distress syndrome (ARDS), irritant induced asthma, occupational asthma, sensory hyper-reactivity, airway (or pulmonary) inflammation, multiple chemical sensitivity, and aid in smoking cessation therapy.
  • Glycopyrrolate micronized premix from example 1 is mixed with Indacaterol hydrochloride, fluticasone propionate and fine grade or micronized Lactose particles in a suitable blender and sifted. If fine lactose not used then mix with half part coarse lactose particles.
  • Blend in Step 1 is mixed with a part of coarse grade lactose monohydrate and then mixed in a suitable blender and sifted.
  • step 2 is filled in a capsule or dose packet or blister.
  • Glycopyrrolate, Indacaterol hydrochloride and fluticasone propionate are mixed with fine grade or micronized Lactose particles, sifted and then mixed in a suitable blender.
  • Coarse grade lactose monohydrate is added to the mixture of Step 1, sifted and then mixed in a suitable blender.
  • step 2 is filled in a capsule or dose packet or blister.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition de poudre sèche inhalable comprenant une quantité efficace de glycopyrronium ou de son sel pharmaceutiquement acceptable ; une quantité efficace d'indacatérol ou de son sel pharmaceutiquement acceptable ; une quantité efficace de fluticasone ou de ses esters pharmaceutiquement acceptables et un diluant, ladite composition étant exempte d'un excipient hydrophobe, leur procédé de préparation et une méthode d'administration pour le traitement de troubles respiratoires chez un sujet. L'invention concerne en outre une composition de poudre sèche inhalable comprenant une quantité efficace de prémélange co-micronisé constitué de bromure de Glycopyronnium et de lactose ; une quantité efficace de chlorhydrate d'Indacatérol ; une quantité efficace de propionate de fluticasone et de lactose, ladite composition étant exempte d'excipients hydrophobes.
PCT/IB2020/053617 2019-04-23 2020-04-16 Composition de poudre sèche inhalable comprenant du glycopyrronium, de l'indacatérol et de la fluticasone WO2020217143A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921016035 2019-04-23
IN201921016035 2019-04-23

Publications (1)

Publication Number Publication Date
WO2020217143A1 true WO2020217143A1 (fr) 2020-10-29

Family

ID=72940702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/053617 WO2020217143A1 (fr) 2019-04-23 2020-04-16 Composition de poudre sèche inhalable comprenant du glycopyrronium, de l'indacatérol et de la fluticasone

Country Status (1)

Country Link
WO (1) WO2020217143A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117064869A (zh) * 2023-09-27 2023-11-17 山东京卫制药有限公司 一种胶囊型吸入粉雾剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267886A1 (en) * 2004-05-18 2008-10-30 Stephen Paul Collingwood Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
WO2012110770A2 (fr) * 2011-02-17 2012-08-23 Cipla Limited Composition pharmaceutique
US20160158150A1 (en) * 2003-09-15 2016-06-09 Vectura Limited Manufacture of Pharmaceutical Compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160158150A1 (en) * 2003-09-15 2016-06-09 Vectura Limited Manufacture of Pharmaceutical Compositions
US20080267886A1 (en) * 2004-05-18 2008-10-30 Stephen Paul Collingwood Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
WO2012110770A2 (fr) * 2011-02-17 2012-08-23 Cipla Limited Composition pharmaceutique

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117064869A (zh) * 2023-09-27 2023-11-17 山东京卫制药有限公司 一种胶囊型吸入粉雾剂及其制备方法

Similar Documents

Publication Publication Date Title
US10314784B2 (en) Compositions of glycopyrronium salt for inhalation
US11090294B2 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
JP6004233B2 (ja) ホスホジエステラーゼ阻害剤を含む乾燥粉末製剤
US8512753B2 (en) Micronized particles of low-dosage strength active agents for powder formulations for inhalation
US10966991B2 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
US10959944B2 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
EA031566B1 (ru) Единичная лекарственная форма в форме композиции сухого порошка, применение единичной лекарственной формы и ингалятор сухого порошка, заполненный единичной лекарственной формой
US20140113888A1 (en) Novel Combination of Therapeutic Agents
US20140116434A1 (en) Dry Powder Inhaler Compositions
WO2016071862A1 (fr) Composition pharmaceutique inhalable comportant du glycopyrronium
WO2020217143A1 (fr) Composition de poudre sèche inhalable comprenant du glycopyrronium, de l'indacatérol et de la fluticasone
WO2017077488A1 (fr) Composition de poudre inhalable à dose fixe comprenant du glycopyrronium et du formotérol
US10350164B2 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
US10786450B2 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20795126

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20795126

Country of ref document: EP

Kind code of ref document: A1